Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review (2024)

Hanning, N., Edwinson, A. L., Ceuleers, H., Peters, S. A., De Man, J. G., Hassett, L. C., De Winter, B. Y. (2021). Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therapeutic Advances in Gastroenterology, 14. https://doi.org/10.1177/1756284821993586

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. / Hanning, Nikita; Edwinson, Adam L.; Ceuleers, Hannah et al.
In: Therapeutic Advances in Gastroenterology, Vol. 14, 2021.

Research output: Contribution to journal › Review article › peer-review

Hanning, N, Edwinson, AL, Ceuleers, H, Peters, SA, De Man, JG, Hassett, LC, De Winter, BY 2021, 'Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review', Therapeutic Advances in Gastroenterology, vol. 14. https://doi.org/10.1177/1756284821993586

Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therapeutic Advances in Gastroenterology. 2021;14. doi: 10.1177/1756284821993586

Hanning, Nikita ; Edwinson, Adam L. ; Ceuleers, Hannah et al. / Intestinal barrier dysfunction in irritable bowel syndrome : a systematic review. In: Therapeutic Advances in Gastroenterology. 2021 ; Vol. 14.

@article{1df21fc60a8e41afba37a050767a0bde,

title = "Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review",

abstract = "Background and Aim: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. Methods: A comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both in vivo and in vitro studies were considered. Results: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17–50%), IBS-D (37–62%) and IBS-C (4–25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). Conclusions: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.",

keywords = "functional gastrointestinal disorders, immune cells, microbiome, occludin, zonula occludens",

author = "Nikita Hanning and Edwinson, {Adam L.} and Hannah Ceuleers and Peters, {Stephanie A.} and {De Man}, {Joris G.} and Hassett, {Leslie C.} and {De Winter}, {Benedicte Y.} and Madhusudan Grover",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

doi = "10.1177/1756284821993586",

language = "English (US)",

volume = "14",

journal = "Therapeutic Advances in Gastroenterology",

issn = "1756-283X",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Intestinal barrier dysfunction in irritable bowel syndrome

T2 - a systematic review

AU - Hanning, Nikita

AU - Edwinson, Adam L.

AU - Ceuleers, Hannah

AU - Peters, Stephanie A.

AU - De Man, Joris G.

AU - Hassett, Leslie C.

AU - De Winter, Benedicte Y.

AU - Grover, Madhusudan

N1 - Publisher Copyright:© The Author(s), 2021.

PY - 2021

Y1 - 2021

N2 - Background and Aim: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. Methods: A comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both in vivo and in vitro studies were considered. Results: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17–50%), IBS-D (37–62%) and IBS-C (4–25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). Conclusions: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

AB - Background and Aim: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. Methods: A comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both in vivo and in vitro studies were considered. Results: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17–50%), IBS-D (37–62%) and IBS-C (4–25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). Conclusions: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

KW - functional gastrointestinal disorders

KW - immune cells

KW - microbiome

KW - occludin

KW - zonula occludens

UR - http://www.scopus.com/inward/record.url?scp=85101739833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101739833&partnerID=8YFLogxK

U2 - 10.1177/1756284821993586

DO - 10.1177/1756284821993586

M3 - Review article

AN - SCOPUS:85101739833

SN - 1756-283X

VL - 14

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

ER -